Related by context. All words. (Click for frequent words.) 66 Bayer HealthCare Onyx Pharmaceuticals 65 FOLFOX6 chemotherapy regimen 64 alvespimycin 64 sorafenib Nexavar ® 64 lintuzumab SGN 64 PI3K/Akt pathway inhibitor 63 BRIM2 63 evaluating tivozanib 63 metastatic colorectal carcinoma 62 evaluating satraplatin 62 paclitaxel carboplatin 62 Panzem R NCD 62 orally inhaled migraine 62 mitoxantrone plus 62 progressive metastatic prostate 62 cisplatin gemcitabine 62 oral chemotherapeutic agent 62 VEGFR2 inhibitor 62 evaluating Xcytrin 62 demonstrated antitumor activity 62 chemotherapy FOLFOX 61 5 fluorouracil leucovorin 61 LymphoStat B belimumab 61 maximally tolerated dose 61 evaluating picoplatin 61 NSABP C 61 evaluating mipomersen 60 pharmacogenomic translational research 60 Xeloda ® 60 XL# SAR# 60 5 FU leucovorin 60 evaluating T DM1 60 clinical trials Archexin 60 TTF Therapy 60 metaglidasen 60 Phase #b/#a clinical 60 sapacitabine CYC# 60 TELINTRA R 60 Targretin capsules 60 refractory colorectal cancer 60 LymphoStat B TM 60 Deforolimus 60 cyclophosphamide doxorubicin vincristine 60 telomerase inhibitor drug 60 HGS ETR2 60 biliary tract cancer 60 gemcitabine Gemzar ® 60 R sorafenib tablets 60 paclitaxel Taxol ® 60 recurrent malignant glioma 59 3D conformal radiation 59 nilotinib Tasigna ® 59 Crofelemer budesonide foam 59 BR.# 59 Panzem NCD 59 ficlatuzumab 59 Recurrent Glioblastoma 59 Quinamed 59 radiation sensitizer 59 including eniluracil ADH 59 recurrent metastatic ovarian cancer 59 PF # [002] 59 prednisone CHOP 59 initiated Phase Ib 59 undergoing elective percutaneous 59 3 registrational trial 59 BRAF inhibitor 59 Epothilone D 59 cisplatin vinorelbine 59 randomized controlled multicenter 59 docetaxel Taxotere R 59 Prednisone Against Refractory 59 EndoTAGTM 1 59 ALN VSP Phase 59 Phase Ib II 59 dimebon latrepirdine 59 gemcitabine carboplatin 59 Budesonide foam crofelemer 59 compound INCB# 58 doxorubicin cyclophosphamide 58 plus prednisone prednisolone 58 AS# amonafide L malate 58 sulfonylurea glimepiride 58 oral ridaforolimus 58 opioid naive 58 Xelox 58 albiglutide 58 MEND CABG II 58 Temodar ® 58 sorafenib Nexavar 58 DCVax ® Brain 58 XL# anticancer compounds 58 Tarceva TM 58 Cloretazine ® 58 CYT# potent vascular disrupting 58 ZOLINZA 58 advanced medullary thyroid 58 gemcitabine Gemzar 58 ® bortezomib 58 evaluating adecatumumab 58 humanised monoclonal antibody 58 Completes Patient Enrollment 58 epirubicin cyclophosphamide 58 Temsirolimus 58 assessing T DM1 58 HGS ETR1 mapatumumab 58 acyclovir Lauriad R 58 generation purine nucleoside 58 alfa 2a 58 AAG geldanamycin analog 58 gemcitabine cisplatin 58 Initiates Phase II 58 receptor tyrosine kinase inhibitor 58 Annamycin 58 TO AVOID PREGNANCY WHILE 58 deforolimus 58 capecitabine Xeloda 58 Platinol ® cisplatin 58 Vidaza ® 58 indolent follicular non 58 relapsed MM 58 liposomal formulation 58 Initiated Phase 58 APEX PD 57 cediranib 57 deCODE AF TM 57 DCVax R 57 antiretroviral naïve 57 Hormone Refractory Prostate Cancer 57 MAGE A3 ASCI 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 initiate Phase Ib 57 trastuzumab DM1 T DM1 57 Investigational Oral 57 initiate Phase IIa 57 intra arterial chemotherapy 57 phase Ib 57 cilengitide 57 de novo kidney transplant 57 Hsp# Inhibitor 57 Folfox 57 teriflunomide 57 oral rivaroxaban 57 Zemplar Capsules 57 Intravitreal 57 plus gemcitabine 57 refractory metastatic colorectal cancer 57 pertuzumab 57 Phase Ib IIa 57 docetaxel Taxotere 57 Tykerb lapatinib 57 Combination REOLYSIN R 57 refractory NSCLC 57 q8h 57 recombinant PSMA vaccine 57 aflibercept VEGF Trap 57 paclitaxel Taxol R 57 ® lenalidomide 57 HGS# 57 metastatic castration resistant 57 Cloretazine R VNP#M 57 metastatic pancreatic 57 stage IIIb IV 57 RhuDex TM 57 sunitinib Sutent 57 clinical trials Archexin ® 57 Empatic ™ 57 recurrent metastatic 57 MIRAPEX ER 57 hypoxia activated prodrug 56 Patients Treated With 56 EDEMA3 trial 56 Aflibercept 56 pediatric pontine glioma 56 Pivotal Phase 56 PTK# 56 ATRA IV 56 virus HCV protease inhibitor 56 trastuzumab Herceptin R 56 NeuroMove TM 56 FUSILEV enhances 56 intravenous RSD# 56 galiximab 56 AKT inhibitor 56 TRIOLEX HE# APOPTONE HE# 56 axitinib 56 blinded randomized placebo controlled 56 Omnitarg 56 metastatic HRPC 56 KRN# 56 patients coinfected 56 REMINYL ® 56 ® natalizumab 56 solid tumors ZYBRESTAT 56 concurrent chemoradiation 56 retinal vein occlusion induced 56 PRIMO CABG 56 Vertex hepatitis C 56 CINQUIL 56 imetelstat GRN#L 56 Initiates Phase 2b 56 registrational Phase 56 Ophena TM 56 resectable pancreatic cancer 56 phase IIb study 56 forodesine 56 naïve HCV 56 iniparib 56 hoFH 56 catheter occlusion 56 multicenter dose escalation 56 neurogenic orthostatic hypotension NOH 56 BRIM3 56 docetaxel chemotherapy 56 Randomized Phase 56 Neuvenge 56 paclitaxel chemotherapy 56 occlusion PAO 56 LBH# 56 relapsed refractory multiple myeloma 56 low dose cytarabine 56 noninvasive outpatient 56 oral prodrug 56 non constipating irritable 56 Achieves Primary Endpoint 56 SPRYCEL ® 56 mg administered orally 55 Omacetaxine 55 Q#IR 55 Gemzar gemcitabine 55 carboplatin paclitaxel 55 Initiate Phase 55 azilsartan medoxomil 55 Aplidin 55 Xeloda capecitabine 55 ELACYT 55 anthracycline taxane 55 plus prednisone 55 TransVax 55 rhIGF-I/rhIGFBP-3 55 signal detection CTSD 55 Meets Primary Endpoint 55 dextromethorphan quinidine 55 Panzem ® 55 metastatic androgen independent 55 dasatinib Sprycel ® 55 evaluating Actimmune 55 adjuvant colon cancer 55 non resectable 55 drug NP2 Enkephalin 55 PLX STROKE targeting 55 sorafenib Nexavar R 55 estramustine 55 systemic lupus erythematosus rheumatoid 55 OvaRex ® MAb 55 humanized therapeutic 55 cortisol synthesis 55 multicenter Phase II 55 ZACTIMA 55 Triapine R 55 #mg/#mg 55 relapsed refractory AML 55 enzastaurin 55 sunitinib malate 55 phase 2a 55 Randomized Phase II 55 Phase 1a clinical 55 CIMZIA TM certolizumab pegol 55 LX# LX# 55 coronary stent merged 55 OvaRex 55 irinotecan cisplatin 55 bevacizumab Avastin R 55 Phase III multicenter 55 glycoprotein IIb IIIa inhibitor 55 EOquin TM phase 55 BrachySil TM 55 prednisone prednisolone plus 55 VELCADE melphalan 55 randomized Phase IIb 55 phase IIa 55 SPEAR Study 55 selective estrogen receptor modulator 55 GEM OS2 55 Elotuzumab 55 FEMALES SHOULD BE ADVISED 55 oral sapacitabine 55 trastuzumab DM1 55 fosbretabulin 55 evaluating REVLIMID 55 Sipuleucel T 55 asymptomatic metastatic 55 novel VDA molecule 55 zoledronic acid Reclast 55 yearly subcutaneous injections 55 tumor xenograft models 55 pharmacokinetic PK study 55 neratinib 55 pan histone deacetylase 55 ancrod 55 Prostate AdenoCarcinoma Treatment 55 HCD# [002] 55 rALLy clinical trial 55 metastatic hormone refractory 55 SUTENT ® 55 PRIMO CABG2 55 REBETOL combination 55 pain palliation 55 induced macular edema 55 dasatinib Sprycel 55 basal insulin analogue 55 DEB# 55 Zenvia ™ 55 chemotherapy fludarabine 55 Stage IIB 55 vincristine doxorubicin 55 phase IIb clinical 55 erlotinib Tarceva R 54 interferon alfa 2a 54 EmbraceAC 54 standard chemotherapy regimens 54 Oral NKTR 54 randomized Phase 2b 54 tanespimycin 54 PEG IFN 54 infliximab monotherapy 54 MKC# MT 54 bortezomib Velcade R 54 evaluating satraplatin plus 54 alpha 2b 54 Safinamide 54 Randomized Double blind 54 ACTEMRA TM 54 IMA# 54 XL# XL# XL# 54 LHRH receptor positive 54 comparing XIENCE V 54 2 methoxyestradiol 54 elotuzumab 54 Adenoscan R 54 cyclophosphamide FC 54 Triapine 54 dose dose escalation 54 FOLFOX chemotherapy 54 8mg/kg 54 ongoing Phase 1b 54 Serdaxin ® 54 plus dexamethasone 54 candidate AQ4N 54 class mGluR5 inhibitor 54 adjuvant cisplatin 54 Vitaxin 54 sarcoma melanoma 54 demonstrated clinically meaningful 54 VNP#M 54 Phase 2a clinical 54 Pharmacokinetics PK 54 non nucleoside inhibitor 54 mg subcutaneous 54 regorafenib 54 CYP#A# CYP#D# 54 GetGoal Phase III 54 PROTECT AF 54 #mg ATC 54 dose escalation Phase 54 exploratory Phase IIa 54 Advaxis Phase 54 stereotactic body 54 pregabalin Lyrica 54 PANVAC VF 54 Launches Generic Version 54 Telik logo TELINTRA 54 MGd 54 Matrix Phase 2b 54 placebo controlled dose escalation 54 aspirin clopidogrel 54 chemotherapy cisplatin 54 anastrazole 54 Albuferon TM 54 Vidaza R 54 undergoing hematopoietic stem 54 treatment naive genotype 54 tenofovir emtricitabine 54 NS5B polymerase 54 5 FU capecitabine 54 lenalidomide dexamethasone 54 bortezomib Velcade 54 MCSP respectively 54 CRLX# 54 orally administered inhibitor 54 #/#/# Cytokinetics Incorporated 54 relapsed myeloma 54 candidate CRLX# 54 omacetaxine mepesuccinate 54 rALLy 54 aleglitazar 54 interferon gamma 1b 54 Vicriviroc 54 INSPIRE Trial Phase III 54 sorafenib tablets 54 midstage clinical 54 Independently Dyax 54 evaluating Vectibix 54 Aeolus Pharmaceuticals Announces 54 ASG 5ME dacetuzumab SGN 54 phase IIb III 54 Proellex TM 54 Phase III ADT 54 Vytorin combines 54 investigational integrase inhibitor 54 bevacizumab Avastin ® 54 IMC A# 54 relapsed ovarian cancer 54 Archexin 54 humanized interleukin 6 54 var arrContent = 54 Multiple Myeloma MM 54 everolimus eluting 54 oral deforolimus 54 Tocosol Paclitaxel 54 Teriflunomide 54 Altera Nebulizer System 54 DU #b 54 mg kg BID 54 mg/m2 cohort 54 confirmatory Phase III 53 Presents Preclinical Data 53 subcutaneous SC 53 Pivotal Phase III 53 Phase III confirmatory 53 IIIa inhibitor 53 FOLFIRI 53 GRN#L 53 recurrent glioblastoma multiforme 53 Cloretazine 53 Onrigin 53 novel oral anticoagulant 53 TBC# 53 nab paclitaxel 53 systemic Phase 1b 53 kidney urologic 53 Multiple Ascending Dose 53 CTA# Injection 53 valsartan amlodipine 53 docetaxel Taxotere ® 53 development peramivir neuraminidase 53 AVOREN 53 relapsed Hodgkin lymphoma 53 tramiprosate Alzhemed TM 53 bone marrow reticulin deposition 53 oral levofloxacin 53 thalidomide Thalomid 53 Pemetrexed 53 Active Ulcerative Colitis 53 lenalidomide Revlimid R 53 metastatic malignant 53 relapsing multiple sclerosis 53 erlotinib Tarceva ® 53 Pazopanib 53 Ragweed Allergy 53 includes TOLAMBA TM 53 initiate Phase 2b 53 Initiates Phase III 53 TASKi3 53 rheumatoid arthritis psoriatic arthritis 53 landmark ATHENA 53 venlafaxine ER 53 Darusentan 53 SYNERGY Stent 53 Phase 1b clinical 53 serologically active systemic lupus 53 transdermal estradiol gel 53 EGS# 53 ThermoDox R 53 XP# XP# 53 CLARITY study 53 Dyloject TM 53 steroid refractory 53 PRESEPT study 53 Novel Oral 53 monoclonal antibody IgG1 Mab 53 non resectable metastatic 53 nonrandomized 53 brand ciclesonide HFA 53 cetuximab Erbitux R 53 intravenous cyclophosphamide 53 Phase Ib clinical trials 53 huN# DM1 53 paclitaxel cisplatin 53 pegylated liposomal doxorubicin 53 Dose Finding 53 abacavir lamivudine 53 pharmacodynamics PD 53 Trofex 53 unique alkylating agent 53 investigational antiplatelet 53 4mg/kg 53 Bevacizumab Avastin 53 Phase III AFFIRM 53 compound KOS 53 EXPAREL TM 53 Pegylated Liposomal Doxorubicin 53 IMiDs ® 53 Initiates Enrollment 53 blind randomized multicenter 53 randomized controlled Phase 53 generation Hsp# inhibitor 53 capecitabine Xeloda R 53 HuMax EGFr 53 ACAPODENE 53 memantine HCl 53 developing Bicifadine serotonin 53 testing huN# DM1 53 pegylated interferon alpha 53 MIST II 53 naltrexone SR 53 epoetin alpha 53 Platinol 53 relapsed multiple myeloma 53 headache nasopharyngitis 53 PEGINTRON TM 53 aspirin heparin 53 ragweed allergy immunotherapeutic 53 oral anti arrhythmic 53 trastuzumab emtansine T DM1 53 IIb clinical trial 53 blind multicenter 53 Initiate Clinical Trial 53 Phase #b/#a 53 Company TAIFUN R 53 ganetespib 53 MEND CABG 53 non valvular atrial 53 mycophenolate mofetil 53 Neulasta R 53 Troxatyl TM 53 PDX pralatrexate 53 Phase 1b clinical trials 53 Pegasys plus Copegus 53 Tekturna HCT ® 53 subcutaneous formulation 53 neutropenic sepsis 53 PD LID 53 visilizumab 53 basal bolus regimen 53 disease progression TTP 53 commercialize CorMedix drug 53 nucleotide analogue 53 Zybrestat 53 CEL SCI Phase III 53 TAXUS Element Paclitaxel Eluting 53 ALGRX 53 Phase Ib clinical 53 opioid induced bowel dysfunction 53 vapreotide acetate 53 clinical trials dacetuzumab SGN 53 Daclizumab 53 CYP#D# inhibitor 53 myocardial infarction ventricular fibrillation 53 clinical trials SGN 53 Bosutinib 53 antiangiogenic agent 53 fallopian tube cancers 53 APPRAISE 52 intravenous REOLYSIN 52 GENASIS clinical 52 commercializes implantable 52 PEGylated irinotecan 52 multicenter Phase III 52 rash pruritus nausea 52 chronic thromboembolic pulmonary 52 adjuvant trastuzumab 52 var arrMeta = 52 prostate cancer HRPC 52 phase IIb 52 pegylated liposomal doxorubicin PLD 52 Peg IFN 52 antihormonal 52 Amrubicin 52 sitagliptin Januvia 52 HGS ETR1 52 EOquin TM 52 novel topoisomerase 52 multicenter randomized controlled 52 ponatinib 52 pegylated interferon alfa 2a 52 intravenous picoplatin 52 TASKi2 52 boosted protease inhibitor 52 ticagrelor Brilinta 52 Phase IIb randomized 52 Phase lll 52 endothelin antagonist 52 EDEMA3 52 iSONEP ™ 52 phase IIa clinical 52 Romiplostim 52 lenalidomide Revlimid 52 T1c 52 mapatumumab 52 RECORD1 52 vidofludimus 52 ocular formulation 52 number NCT# ClinicalTrials.gov 52 Dual Opioid 52 pharmacologically active isomer 52 Resolute stent 52 Entereg R 52 antiangiogenesis therapies 52 Phase IIb III 52 hormone refractory metastatic prostate 52 pralatrexate injection folate analogue 52 dose escalation trial 52 generation DACH Platinum 52 subcutaneous methylnaltrexone 52 NVA# 52 controlled multicenter Phase 52 Tasigna prolongs 52 EVIZON ™ 52 intravesical infusion therapy 52 genotypic resistance 52 PROTEGE 52 Harry Palmin President 52 potentially hepatotoxic 52 systemic RNAi therapeutic 52 observer blinded randomized 52 placebo controlled multicenter 52 BRCA deficient 52 dose regimens 52 GW# [003] 52 investigational antiplatelet agent 52 Sular ® 52 NSABP B 52 Novartis Afinitor 52 3TC lamivudine Epivir 52 pioglitazone HCl 52 Ketotransdel 52 myeloid metaplasia 52 prospective multicenter randomized 52 vinca alkaloid 52 PCI ExTRACT TIMI 52 brivanib 52 Prescription acetaminophen 52 dose escalation clinical 52 Imprime PGG 52 Imatinib Mesylate 52 NIC #G 52 REGN# 52 briakinumab 52 Phase Ib study 52 multi kinase inhibitor 52 Emtriva Viread 52 integrin inhibitor 52 Pruvel TM 52 Akt inhibitor 52 confirmatory clinical 52 Cloretazine R 52 Ereska 52 Pharmacokinetic parameters 52 MYDICAR ® 52 thetreatment 52 liposomal doxorubicin 52 phase IIb trial 52 placebo controlled clinical 52 CML CP 52 Picoplatin Efficacy After 52 ORENCIA ® 52 Locteron ® 52 LAB CGRP 52 Vidaza azacitidine 52 Mg Usa 52 weekly subcutaneous injections 52 tolevamer 52 6 sulfatase 52 multicenter multinational 52 CAMMS# 52 OMS# 52 MKC# MKC# PP 52 orally inhaled 52 Femara letrozole 52 pegylated interferons 52 Motexafin Gadolinium 52 Unstable Angina 52 SPP# Rasilez 52 ORAL Sync 52 Aryplase 52 ENL recurrence 52 Phase 2b Clinical Trial 52 ORAL Solo 52 papillary renal cell carcinoma 52 aliskiren amlodipine 52 aplindore 52 EXPLORE Xa 52 R ferumoxytol Injection 52 Phase III metastatic melanoma 52 IMPACT DCM 52 recurrent GBM 52 multicenter Phase 52 lorvotuzumab mertansine 52 drug tesmilifene 52 davunetide intranasal AL 52 multicenter randomized placebo controlled 52 vascular disrupting agent 52 DCVax Brain 52 Camptosar ® 52 painkiller Valium 52 bazedoxifene conjugated estrogens 52 Flu Cy 52 ADVEXIN therapy 52 intermittent dosing 52 Telintra 51 taxane resistant 51 interstitial brachytherapy 51 reslizumab 51 Fovea Pharmaceuticals subsidiary 51 eluting stent 51 Phase IIa trials 51 double blinded randomized 51 dose escalation phase 51 cetuximab Erbitux 51 Phase IIIb 51 R#/MEM # 51 RCW breast cancer 51 Phase 2b kidney transplant 51 AIR CF2 51 sunitinib Sutent ® 51 retinal thrombosis hemorrhages 51 systemically administered 51 Rigel R# 51 phase IIIb 51 R olmesartan medoxomil 51 acute mania 51 Trial Evaluating 51 cardiac resynchronisation therapy 51 HCV NS5B polymerase 51 intravenous bolus 51 refractory myeloma 51 nucleoside polymerase inhibitor 51 BLOOM DM 51 fistulizing Crohn disease 51 phase III isavuconazole 51 Roflumilast 51 TransVax tm 51 Mg Uk 51 5 Fluorouracil 51 DEEP AF 51 fidaxomicin Phase 3 51 davalintide 51 antiangiogenic therapy 51 Diabetic Macular Edema DME 51 IMiDs R 51 Phase IIIb clinical 51 multicenter prospective 51 FOLOTYN ® 51 Capesaris 51 DAC HYP 51 Revascor TM 51 signal transduction inhibitor 51 Anturol TM 51 CUSTOM III 51 Sapacitabine 51 RELOVAIR ™ 51 Doxil ® 51 Phase III placebo controlled 51 investigational humanized monoclonal antibody 51 Chemophase 51 modified REGENESIS Phase IIb 51 ABSORB trial 51 Study Evaluating 51 Aztreonam lysine 51 Phase III ThermoDox 51 lapatinib Tykerb 51 hypercholesterolemic patients 51 dexamethasone Decadron 51 known dihydropyrimidine dehydrogenase 51 Surgical resection 51 bendamustine 51 ChronVac C 51 Naive Patients 51 IMiDs 51 Pimavanserin 51 somatostatin analog 51 lumiliximab 51 Maximum Tolerated Dose MTD 51 implantable centrifugal rotary 51 Phase 2b clinical 51 randomized #:#:# 51 Phase 1b 51 PEGylated docetaxel 51 adenosine injection 51 Selzentry Celsentri 51 Pafuramidine 51 serotonin norepinephrine reuptake inhibitor 51 Edge STudy 51 acute peripheral arterial 51 Initiate Phase II 51 preclinical efficacy 51 PEG SN# 51 HCl capsules 51 potent triglyceride lowering 51 5mg #mg 51 LUCENTIS 51 pivotal bioequivalence 51 velafermin 51 acting angiotensin 51 MVax 51 evaluating MGCD# [002] 51 PEGINTRON REBETOL combination 51 cromolyn sodium 51 sufentanil 51 Xanafide 51 TroVax ® 51 CLORETAZINE TM VNP#M 51 isoform selective 51 Ribavirin causes 51 efavirenz EFV 51 orBec 51 treatment naïve genotype 51 TAFA# 51 investigational monoclonal antibody 51 immunotherapeutic vaccine 51 liposomal amphotericin B 51 PresbyLens ® 51 PROMUS Element Stent 51 DIRECT Trial 51 Corlux 51 ToGA 51 ACE Inhibitor 51 sodium thiosulfate STS 51 seliciclib CYC# 51 small molecule chemotherapeutic 51 fidaxomicin Phase 51 statistically significant superiority 51 neurologic progression 51 atrial fibrillation budiodarone ATI 51 daily Infergen 51 oral antiplatelet therapy 51 Fulvestrant 51 Phase IIb REGENESIS 51 placebo controlled Phase III 51 ENMD # 51 phase Ib clinical 51 SPIRIT FIRST 51 rabeprazole 51 Hycamtin ® 51 #mg QD [002] 51 hour bronchodilation 51 Alequel ™ 51 BrachySil ™ 51 oral vancomycin 51 PORxin TM platforms 51 bicifadine 51 SIMPADICO 51 Vaxfectin formulated 51 HDL Selective Delipidation 51 Oral Fingolimod 51 desvenlafaxine succinate 51 symptomatic paroxysmal AF 51 sequential dose escalation 51 lamotrigine Lamictal 51 REVIVE TA 51 ONCONASE R 51 neo adjuvant 51 chemotherapeutic regimen 51 Phase #b/#a trial 51 R# #mg BID 51 denileukin diftitox 51 ReN# stem cell 51 mcg BID 51 Transgenomic Pharmacogenomics Services 51 Vorapaxar 50 iloprost synthetic compound 50 DermaVir Patch 50 MiStent DES 50 dual endothelin receptor antagonist 50 carotid endarterectomy CEA 50 humanised antibody 50 HIV treatments Reyataz 50 Stage IIIb 50 Antisoma AS# 50 IAP inhibitor 50 Phase IIb clinical trials 50 cinacalcet 50 Pegylated Interferon 50 Roche Xeloda 50 zaleplon 50 GRNVAC1 50 Amoxicillin PULSYS Phase III 50 alendronate Fosamax 50 induced oral mucositis 50 ABSORB clinical 50 IIa trials 50 ergot derivatives 50 doxorubicin docetaxel 50 OncoVex 50 refractory CLL 50 DG# compounds targeting 50 Phase 2b clinical trials 50 Custom NX 50 finasteride Proscar 50 CATIE AD 50 ZYBRESTAT fosbretabulin 50 AZT 3TC 50 Dabigatran etexilate 50 dose escalation 50 cancer indications bafetinib 50 inhalations twice 50 either acutely decompensated 50 Phase IIA 50 Hepsera adefovir dipivoxil 50 Androxal TM 50 vasomotor symptoms associated 50 CHAMPION PCI 50 Tekamlo 50 PROTECT II 50 TMC# C# 50 peginterferon alfa 2b 50 Phase III Pivotal 50 invasive lobular carcinoma 50 patientswith 50 Temodar temozolomide 50 Drug Fails 50 dosing cohorts 50 AIR CF1 50 double blinded placebo 50 keloid scarring 50 MVA MUC1 IL2 50 drotrecogin alfa activated 50 Imprime PGG ® 50 icatibant 50 novel chimeric natriuretic 50 pharmacodynamic PD 50 small molecule glucokinase 50 selective phosphodiesterase 50 cetrorelix pamoate 50 telaprevir dosed 50 investigational HCV polymerase 50 PRECISE trial 50 hyaluronidase enzyme 50 THR beta agonist 50 ELIQUIS 50 neoadjuvant setting 50 Myocardial Infarction Study 50 clonidine hydrochloride 50 Removab 50 Dose Ranging Study 50 Intervention Effectiveness 50 HMG CoA reductase inhibitors 50 Romidepsin 50 AEGR 50 neoadjuvant treatment 50 iii GTx 50 donepezil Aricept 50 Anti VEGF 50 imexon 50 naloxol derivative 50 FOLFIRI chemotherapy 50 Pharma Merck Serono 50 Pivotal Trial 50 trial evaluating PRX# 50 TAXUS Liberté 50 Patients Receiving 50 OnDose 50 peginterferon alpha 2a 50 dacarbazine 50 Intravail R 50 targeted protein kinase 50 Vascugel ® 50 SYN# 50 AFRS TM 50 Accelerated Partial Breast Irradiation 50 refractory gout 50 multicenter placebo controlled 50 Kinesin Spindle Protein KSP 50 Almorexant 50 prostate cancer mCRPC 50 ACCEDE 50 Pertuzumab 50 TAXUS IV 50 delta opioid receptor 50 anti arrhythmic 50 Spiegelmer ® 50 placebo controlled Phase 50 MIVI III 50 EVEREST II 50 OHR/AVR# 50 TMC# r 50 Enzastaurin 50 helical TomoTherapy 50 primary hypercholesterolemia 50 Atripla combines 50 ENDEAVOR III 50 Randomized Double Blind 50 everolimus eluting stents 50 GV# [001] 50 mildly symptomatic 50 brivaracetam 50 IL# PE#QQR 50 CRMD#